BrightPath and Cellistic have entered an agreement to progress the CAR-T cell therapy platform into clinical trials.

Incyclix Bio has reported outcomes from the dose escalation part of the Phase I/II INX-315-01 trial of INX-315 for breast cancer treatment.

Mesoblast Limited recently announced positive Phase III trial results in the European Journal of Heart Failure.

The US FDA has granted clearance to SpliceBio’s IND application to begin the trial of SB-007, designed for Stargardt disease treatment.

The Phase I expansion Mythic trial saw a 25.9% overall response rate for endometrial cancer and 37.5% in platinum-resistant ovarian cancer.

Trevi has announced that its Phase IIb trial of Haduvio in treating IPF subjects with chronic cough will continue without sample size change.

SK bioscience has gained Australia’s Human Research Ethics Committee (HREC) approval to begin Phase I/II clinical trials of GBP560.

The WHO’s guidance provides direction on diversity and how to include patients who are pregnant, lactating and from low-middle income countries.

Results found that IBRANCE was able to see medical profession free survival extended by an additional 15 months. Credit: Shutterstock / ShU studio Healthcare giant Pfizer’s IBRANCE (palbociclib) as a ...

There must be a renewed focus on older patients with symptoms that match MS. Credit: imtmphoto via Shutterstock. Multiple sclerosis (MS) is a chronic disease of the central nervous system that occurs ...

Topline data presented yesterday (12 December) considered 36 patients eligible for safety and efficacy evaluation at 29 October. Credit: Jo Panuwat D / Shutterstock. iTeos Therapeutics has announced ...

Early results from Blue Lake trial found the vaccine to be safe, tolerated and able to cut the chance of contracting the infection.